NewCelX

Company Overview

Snapshot

Founded in October 2008 by Michel Revel, NewCelX operates with 11–50 employees. The company has raised a total of $45.35 million across 9 funding rounds from 11 investors. In October 2025, NewCelX completed a merger with NLS Pharmaceutics Ltd. and subsequently became public on NASDAQ.

Business overview

NewCelX is a biotechnology company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company leverages an integrated platform that combines advanced stem-cell technologies with neuroscience expertise to create scalable, regenerative treatments. NewCelX's core products, IsletRx and AstroRx, target conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes, serving the Health Tech & Life Sciences sector, particularly in pharmaceuticals within the United States market.

Strategic signal

In October 2025, NewCelX completed its merger with NLS Pharmaceutics Ltd. and began trading on NASDAQ. This strategic move signifies a major corporate restructuring and market expansion for NewCelX, positioning it as a publicly traded entity with potentially enhanced access to capital and broader market visibility for its cell-based and small-molecule therapies.

Company Intelligence Q&A

What was a significant corporate development for NewCelX in late 2025?

In October 2025, NewCelX completed its merger with NLS Pharmaceutics Ltd. and became public on NASDAQ. This event followed shareholder approval of the merger in September 2025.

What was the outcome of the collaboration between NLS Pharmaceutics and Kadimastem regarding a Hong Kong patent?

In September 2025, NLS Pharmaceutics and Kadimastem announced a Hong Kong patent covering cell-selection and enrichment technology for IsletRx, a treatment for diabetes patients.

What regulatory milestone did NewCelX achieve in May 2026?

In May 2026, NewCelX Ltd. submitted a Pre-IND (Investigational New Drug) package to the FDA for NCEL-101, intended for the treatment of Type 1 Diabetes.

What strategic collaboration did NewCelX announce in October 2025?

In October 2025, NewCelX and Kadimastem announced a strategic collaboration with TargetGene to advance next-generation gene-edited cell therapies.

What was the outcome of the BIRD Foundation's support for the ITOL-102 diabetes program in July 2025?

In July 2025, the BIRD Foundation approved an additional milestone payment to Kadimastem and iTolerance for the continued co-development of the ITOL-102 Type 1 Diabetes cell therapy program.